You are now leaving our website and heading to a third-party website that we do not operate. We are not responsible for the content of the third-party website. You are advised to review its privacy policy as it may differ from ours.
Are you sure you want to leave?
Cancel
Do ND-CKD patients with SHPT need a higher level of vitamin D compared with the general population?
Explore both sides of this important question by watching ‘The vitamin D debate in CKD and SHPT: how high should we aim?’
What's the debate about?
Held at the 2019 American Society of Nephrology (ASN) Kidney Week, Washington, DC, the debate on the optimal vitamin D target in non-dialysis chronic kidney disease (ND-CKD) patients with secondary hyperparathyroidism (SHPT) focuses on answering three important questions:
- Do patients with ND-CKD need a higher level of vitamin D compared with the general population?
- If so, is the higher level necessary to manage SHPT?
- What is the best way to give vitamin D to ND-CKD patients?
The event begins with an introduction by Michal Melamed, Associate Professor at the Albert Einstein College of Medicine, New York, who lays the foundation for the debate by presenting background information about CKD, SHPT and vitamin D therapy.
This is followed by a presentation by James B Wetmore, Associate Professor at the University of Kansas, Kansas, who argues that a higher vitamin D level is needed to manage SHPT in ND-CKD patients. He highlights that the current target 25D level is based on the general population; however, ND-CKD patients may not be able to achieve this without treatment because the physiology of their parathyroid glands is altered. To support this, Associate Professor Wetmore points to the association between low glomerular filtration rate (GFR) and the proportion of patients with 25D levels lower than 37.4 nmol/L (15 ng/mL).
The arguments posited by Associate Professor Wetmore are then countered in a presentation by Julia Scialla, Associate Professor at the University of Virginia, Virginia, who believes that a lower vitamin D level is better than a higher level for ND-CKD patients. She argues that, in line with current guidelines, vitamin D should be used to reduce the burden of SHPT without increasing the risks of other complications, and no significant benefit of a higher 25D level on PTH levels, bone disease or fractures has been observed. Associate Professor Scialla suggests that higher vitamin D levels could help to treat SHPT in ND-CKD patients, but only in special cases.
Both Wetmore and Scialla then engaged in a lively discussion, with questions from the audience.
The debate, which was sponsored by OPKO Pharmaceuticals, LLC, is now available on the ASN website for all to benefit. Watch it right now and get the latest understanding of optimal vitamin D targets in ND-CKD patients with SHPT.
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Ltd., a company of the Vifor Pharma Group, is the partner of choice for renal pharmaceutical and innovative, patient-focused solutions. The Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. The Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care. For more information about Vifor Pharma, please visit www.viforpharma.com
This site does not provide medical advice and may not be relied upon by any healthcare practitioner in exercising his or her professional judgement in the practice of medicine. The information provided herein is provided for general educational purposes only, and is not to be used or relied on for any diagnostic or treatment purposes. This material is not intended to represent the best or only methods or procedures appropriate for the medical situations discussed; rather the material is intended to present an approach, view, statement or opinion of the authors or presenters, which may be helpful or of interest to other practitioners. VFMCRP makes no warranties or representations as to the site's accuracy, completeness or up-to-date information. All users agree that access to this site is at their own risk, and that neither VFMCRP any party involved in creating or delivering this site shall be liable for damages of any kind, including without limitation, any special, direct or indirect, incidental, or consequential or punitive damages (even if VFMCRP has been advised of the possibility of such damages) arising out of access to, or use of the information contained on this site, or any errors or omissions, misprints, out-of-date information, technical or pricing inaccuracies, typographical or other errors appearing on this site. This limitation includes damages to, or for any viruses that may infect your computer equipment.
© 2021 Vifor Fresenius Medical Care Renal Pharma
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Ltd., a company of the Vifor Pharma Group, is the partner of choice for renal pharmaceutical and innovative, patient-focused solutions. The Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology …
Read More
